| Literature DB >> 32998401 |
Megan E Rollo1,2, Jennifer N Baldwin1,2, Melinda Hutchesson1,2, Elroy J Aguiar3, Katie Wynne4,5, Ashley Young6, Robin Callister2,7, Rebecca Haslam1,2, Clare E Collins1,2.
Abstract
Self-administered eHealth interventions provide a potential low-cost solution for reducing diabetes risk. The aim of this pilot randomised controlled trial (RCT) was to evaluate the feasibility, including recruitment, retention, preliminary efficacy (primary outcome) and acceptability (secondary outcome) of the "Body Balance Beyond" eHealth intervention in women with previous gestational diabetes mellitus (GDM). Women with overweight/obesity who had recent GDM (previous 24 months) were randomised into one of three groups: 1) high personalisation (access to "Body Balance Beyond" website, individual telehealth coaching via video call by a dietitian and exercise physiologist, and text message support); 2) low personalisation (website only); or 3) waitlist control. To evaluate preliminary efficacy, weight (kg), glycosylated hemoglobin, type A1C (HbA1c), cholesterol (total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL)), diet quality and moderate-vigorous physical activity were analysed at baseline and at 3 and 6 months using generalised linear mixed models. To investigate acceptability, process evaluation was conducted at 3 and 6 months. Of the 327 potential participants screened, 42 women (mean age 33.5 ± 4.0 years and BMI 32.4 ± 4.3 kg/m2) were randomised, with 30 (71%) completing the study. Retention at 6 months was 80%, 54% and 79% for high personalisation, low personalisation and waitlist control, respectively (reasons: personal/work commitments, n = 4; started weight-loss diet, n = 1; pregnant, n = 1; resources not useful, n = 1; and not contactable, n = 5). No significant group-by-time interactions were observed for preliminary efficacy outcomes, with the exception of HDL cholesterol, where a difference favoured the low personalisation group relative to the control (p = 0.028). The majority (91%) of women accessed the website in the first 3 months and 57% from 4-6 months. The website provided useful information for 95% and 92% of women at 3 and 6 months, respectively, although only a third of women found it motivating (30% and 25% at 3 and 6 months, respectively). Most women agreed that the telehealth coaching increased their confidence for improving diet (85%) and physical activity (92%) behaviours, although fewer women regarded the text messages as positive (22% and 31% for improving diet and physical activity, respectively). The majority of women (82% at 3 months and 87% at 6 months) in the high personalisation group would recommend the program to other women with GDM. Recruiting and retaining women with a recent diagnosis of GDM is challenging. The "Body Balance Beyond" website combined with telehealth coaching via video call is largely acceptable and useful for women with recent GDM. Further analysis of the effect on diabetes risk reduction in a larger study is needed.Entities:
Keywords: diet; exercise; gestational diabetes; prevention; type 2 diabetes mellitus; weight loss
Mesh:
Year: 2020 PMID: 32998401 PMCID: PMC7579575 DOI: 10.3390/ijerph17197115
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Study protocol for a 6-month pilot randomised controlled trial for women with recent gestational diabetes mellitus (GDM) who were at risk of developing Type 2 diabetes mellitus (T2DM).
Figure 2Consolidated Standards of Reporting Trials (CONSORT) diagram showing the flow of participants in a 6-month pilot randomised controlled trial for women with recent GDM who were at risk of developing T2DM.
Baseline characteristics of women randomised to the high personalisation, low personalisation and waitlist control groups in a 6-month pilot randomised controlled trial for women with recent GDM who were at risk of developing T2DM: data are presented as % (n) or mean ± SD.
| High Personalisation | Low Personalisation | Waitlist Control | |
|---|---|---|---|
| ( | ( | ( | |
|
| |||
| Age | 34.0 ± 4.5 | 32.8 ± 3.6 | 33.6 ± 3.8 |
| Country of birth | |||
| Australia | 93.3 (14) | 100 (13) | 92.9 (13) |
| Highest qualification completed | |||
| School certificate (year 10 or equivalent) | 6.7 (1) | 0 | 14.3 (2) |
| Certificate/diploma/trade | 26.7 (4) | 30.8 (4) | 35.7 (5) |
| University degree | 60.0 (9) | 69.2 (9) | 50 (7) |
| Marital status | |||
| Married/de facto | 93.3 (14) | 100 (13) | 100 (14) |
| Never married | 6.7 (1) | 0 | 0 |
| Household income | |||
| <$1000 weekly | 6.7 (1) | 0 | 7.1 (1) |
| $1000–$1999 weekly | 46.7 (7) | 38.5 (5) | 35.7 (5) |
| >$2000 weekly | 33.3 (5) | 53.8 (7) | 57.1 (8) |
| Do not know/decline to answer | 13.3 (2) | 7.7 (1) | 0 |
| Ability to manage on current income | |||
| Difficult some of the time | 46.7 (7) | 15.4 (2) | 35.7 (5) |
| Not too bad/easy | 53.4 (8) | 84.6 (11) | 64.3 (9) |
| Current smoker (less than once per week) | 0 | 7.7 (1) | 0 |
|
| |||
| Parity | 2.1 ± 1.2 | 1.6 ± 1.0 | 1.7 ± 0.6 |
| Months since first GDM diagnosis | 14.4 ± 10.1 | 11.6 ± 5.6 | 12.2 ± 4.9 |
|
| |||
| Diet | 93.3 (14) | 92.3 (12) | 71.4 (10) |
| Exercise | 40.0 (6) | 46.2 (6) | 28.6 (4) |
| Tablets | 0 | 7.7 (1) | 0 |
| Insulin | 66.7 (10) | 46.2 (6) | 64.3 (9) |
|
| |||
| Pre-eclampsia | 20.0 (3) | 23.1 (3) | 7.1 (1) |
| PCOS | 20.0 (3) | 23.1 (3) | 7.1 (1) |
| Low thyroid hormone levels | 6.7 (1) | 0 | 7.1 (1) |
| Other condition: cholestasis of pregnancy | 0 | 7.7 (1) | 0 |
|
| |||
| Height (m) | 1.66 ± 0.10 | 1.62 ± 0.10 | 1.65 ± 5.60 |
| Weight (kg) | 91.1 ± 15.9 | 89.3 ± 12.5 | 83.8 ± 10.7 |
| BMI (kg/m2) | 32.8 ± 4.1 | 33.9 ± 3.6 | 31.1 ± 4.8 |
| BMI category, % (n) | |||
| Overweight | 26.7 (4) | 23.1 (3) | 28.6 (4) |
| Obese | 73.3 (11) | 76.9 (10) | 57.1 (8) |
| Waist circumference (cm) | 101.5 ± 12.2 | 103.0 ± 10.6 | 96.3 ± 8.1 |
| Body fat mass (kg) | 35.7 ± 9.6 | 39.1 ± 10.2 | 40.4 ± 11.2 |
| Skeletal muscle mass (kg) | 26.7 ± 3.2 | 27.3 ± 2.9 | 28.1 ± 3.8 |
|
| |||
| HbA1c % | 5.1 ± 0.3 | 5.1 ± 0.4 | 5.1 ± 0.3 |
| Fasting blood glucose (mmol/L) | 4.8 ± 0.3 | 4.7 ± 0.5 | 4.9 ± 0.4 |
| Fasting insulin (mU/L) | 7.8 ± 3.0 | 10.3 ± 5.0 | 6.1 ± 2.6 |
| HOMA2-IR | 1.0 ± 0.4 | 1.3 ± 0.6 | 0.8 ± 0.3 |
| QUICKI | 0.36 ± 0.02 | 0.35 ± 0.03 | 0.37 ± 0.03 |
| LDL cholesterol (mmol/L) | 3.4 ± 1.2 | 3.2 ± 0.7 | 3.7 ± 1.0 |
| HDL cholesterol (mmol/L) | 1.4 ± 0.3 | 1.3 ± 0.3 | 1.5 ± 0.3 |
| Total cholesterol/HDL ratio | 3.8 ± 0.8 | 4.2 ± 1.1 | 4.1 ± 1.2 |
| Triglycerides (mmol/L) | 1.1 ± 0.4 | 1.2 ± 0.7 | 1.2 ± 0.5 |
|
| |||
| Systolic blood pressure (mmHg) | 104.4 ± 8.2 | 109.4 ± 9.4 | 106.4 ± 10.2 |
| Diastolic blood pressure (mmHg) | 67.5 ± 6.1 | 69.3 ± 5.6 | 68.6 ± 7.3 |
|
| |||
| ARFS total score (maximum 73) | 34.7 ± 6.4 | 39.0 ± 10.3 | 34.2 ± 7.0 |
| % energy: core foods | 57.4 ± 11.1 | 62.9 ± 7.0 | 60.9 ± 12.6 |
| % energy: non-core foods | 42.6 ± 11.1 | 37.1 ± 7.0 | 39.1 ± 12.6 |
| % energy: protein | 18.7 ± 2.8 | 21.3 ± 3.0 | 18.6 ± 3.2 |
| % energy: carbohydrate | 45.7 ± 4.7 | 39.7 ± 4.2 | 43.9 ± 6.6 |
| % energy: fats | 35.1 ± 3.6 | 38.8 ± 3.7 | 33.6 ± 14.4 |
| % energy: saturated fats | 15.5 ± 2.4 | 17.4 ± 2.6 | 14.1 ± 1.8 |
| % energy: alcohol | 1.3 ± 2.2 | 1.0 ± 1.6 | 4.1 ± 5.0 |
|
| |||
| MVPA (minutes/week) | 74.3 ± 87.1 | 144.2 ± 114.4 | 130.0 ± 116.7 |
| Resistance training frequency | |||
| None | 86.7 (13) | 69.2 (9) | 57.1 (8) |
| 1–2 times per week | 6.7 (1) | 23.1 (3) | 7.1 (1) |
| 3 or more times per week | 6.7 (1) | 7.7 (1) | 35.7 (5) |
| Pelvic floor exercise frequency | |||
| None | 53.3 (8) | 69.2 (0) | 42.9 (6) |
| 1–2 times per week | 13.3 (2) | 15.4 (2) | 35.7 (5) |
| 3 or more times per week | 20.0 (5) | 15.4 (2) | 21.4 (3) |
|
| |||
| WEL-SF (maximum 90) | 43.9 ± 19.7 | 51.5 ± 16.5 | 46.6 ± 14.4 |
| Self-Efficacy for Exercise score (maximum 11) | 5.9 ± 1.9 | 5.8 ± 2.2 | 6.0 ± 2.5 |
| AQoL-6D utility score (maximum 1.0) | 0.76 ± 0.11 | 0.78 ± 0.11 | 0.80 ± 0.20 |
Abbreviations: AQoL, Assessment of Quality of Life 6-dimension; ARFS, Australian Recommended Food Score; BMI, body mass index; GDM, gestational diabetes mellitus; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; HOMA-IR2, homeostatic model assessment of insulin resistance; LDL low-density lipoprotein, MVPA, moderate to vigorous physical activity; PCOS, polycystic ovarian syndrome; QUICKI, quantitative insulin sensitivity check index; SD, standard deviation; and WEL-SF, Weight Efficacy Lifestyle Questionnaire-Short Form.
Mean (95% CI) change in preliminary efficacy outcomes within groups and between groups (intention-to-treat population) over time in a 6-month pilot randomised controlled trial for women with recent GDM who were at risk of developing T2DM.
| Change from Baseline, Mean (95% CI) a | Difference between Groups, Mean (95% CI) b | |||||||
|---|---|---|---|---|---|---|---|---|
| Outcome | Month | High Personalisation | Low Personalisation | Waitlist Control | High Personalisation vs. Waitlist Control | Low Personalisation vs. Waitlist Control | High vs. Low Personalisation | |
| Weight (kg) c | 3 | −1.30 (−0.50, 3.10) | −0.91 (−3.15, 1.32) | 1.11 (−1.08, 3.29) | −2.41 (−5.24, 0.42) | −2.02 (−5.15, 1.11) | −0.39 (−3.26, 2.48) | 0.391 |
| 6 | −1.60 (−3.50, 0.31) | −0.90 (−3.36, 1.57) | 0.75 (−1.27, 2.78) | −2.35 (−5.13, 0.43) | −1.65 (−4.84, 1.54) | −0.70 (−3.81, 0.43) | ||
| HbA1c (%) | 3 | 0.02 (−0.07, 0.11) | 0.04 (−0.08, 0.15) | 0.09 (−0.02, 0.20) | −0.07 (−0.21, 0.07) | −0.05 (−0.21, 0.10) | −0.01 (−0.15, 0.13) | 0.673 |
| 6 | 0.06 (−0.03, 0.16) | 0.02 (−0.10, 0.14) | 0.11 (0.01, 0.21) | −0.05 (−0.19, 0.09) | −0.09 (−0.25, 0.07) | 0.04 (−0.11, 0.20) | ||
| Total cholesterol (mmol/L) | 3 | −0.34 (−0.74, 0.06) | −0.37 (−0.86, 0.12) | −0.02 (−0.50, 0.47) | −0.32 (−0.95, 0.31) | −0.35 (−1.04, 0.34) | 0.03 (−0.61, 0.67) | 0.769 |
| 6 | −0.30 (−0.72, 0.13) | −0.38 (−0.92, 0.16) | −0.34 (−0.79, 0.11) | 0.04 (−0.58, 0.66) | −0.04 (−0.74, 0.67) | 0.08 (−0.61, 0.77) | ||
| HDL cholesterol (mmol/L) | 3 | −0.09 (−0.19, 0.02) | 0.02 (−0.11, 0.15) | 0.03 (−0.10, 0.16) | −0.12 (−0.28, 0.05) | −0.01 (−0.19, 0.17) | −0.10 (−0.27, 0.06) |
|
| 6 | −0.11 (−0.22, 0.01) | −0.06 (−0.20, 0.08) | −0.25 (−0.37, −0.13) | 0.14 (−0.02, 0.31) |
| −0.05 (−0.23, 0.13) | ||
| Triglycerides (mmol/L) d | 3 | −0.02 (−0.20, 0.15) | 0.01 (−0.21, 0.22) | −0.07 (−0.28, 0.14) | 0.04 (−0.23, 0.32) | 0.08 (−0.23, 0.38) | −0.03 (−0.31, 0.25) | 0.091 |
| 6 | −0.14 (−0.33, 0.04) | −0.01 (−0.25, 0.23) | 0.18 (−0.02, 0.37) | −0.06 (−0.23, 0.11) | −0.14 (−0.32, 0.06) | 0.07 (−0.11, 0.26) | ||
| ARFS (maximum 73) | 3 | 0.87 (−2.24, 3.98) | −1.08 (−4.91, 2.74) | −1.90 (−5.50, 1.71) | 2.77 (−2.03, 7.57) | 0.81 (−4.48, 6.11) | 1.95 (−3.01, 6.92) | 0.274 |
| 6 | 1.79 (−1.41, 4.99) | 2.89 (−1.10, 6.89) | −2.00 (−5.48, 1.47) | 3.79 (−0.97, 8.55) | 4.89 (−0.44, 10.23) | −1.11 (−6.26, 4.05) | ||
| % energy: core d | 3 | 10.48 (5.00, 15.96) | 6.11 (−0.45, 12.68) | 0.72 (−5.76, 7.19) | 9.73 (1.26, 18.20) | 4.87 (−4.36, 14.10) | 4.86 (−3.68, 13.40) | 0.143 |
| 6 | 8.51 (1.31, 15.71) | 8.51 (1.31, 15.71) | 3.12 (−2.91, 9.14) | 9.29 (0.96, 17.62) | 4.99 (−4.41, 14.39) | 4.30 (−4.92, 13.53) | ||
| % energy: non-core d | 3 | −10.48 (−5.00, −15.96) | −6.11 (−12.68, 0.45) | −0.72 (−7.19, 5.76) | −9.73 (−18.20, −1.26) | −4.87 (−14.10, 4.36) | −4.86 (−13.40, 3.68) | 0.143 |
| 6 | −8.51 (−1.31, −15.71) | −8.51 (−15.71, 1.31) | −3.12 (−9.14, 2.91) | −9.29 (−17.62, −0.96) | −4.99 (−14.39, 4.41) | −4.30 (−13.53, 4.92) | ||
| MVPA (min/week) d | 3 | 60.17 (−10.67, 131.01) | −21.68 (−108.05, 64.69) | −21.30 (−107.25, 64.65) | 82.06 (−173.44, 337.56) | 11.32 (−264.43, 287.08) | 70.74 (−186.78, 328.26) | 0.158 |
| 6 | 182 (−35, 400) | −78 (−360, 230) | −42 (−269, 232) | 244 (−8, 496) | 52 (−228, 333) | 191 (−84, 467) | ||
Abbreviations: AQoL = Assessment of Quality of Life 6-dimension; ARFS = Australian Recommended Food Score; BMI = body mass index; CI = confidence interval; GDM = gestational diabetes mellitus; HbA1c = glycated haemoglobin; HDL = high-density lipoprotein; HOMA-IR2 = homeostatic model assessment of insulin resistance; LDL = low-density lipoprotein; MVPA = moderate to vigorous physical activity; QUICKI = quantitative insulin sensitivity check index; SEE = Self-Efficacy for Exercise; T2DM = type 2 diabetes mellitus; and WEL-SF = Weight Efficacy Lifestyle Questionnaire-short form. a Time differences were calculated as 3 months minus baseline and 6 months minus baseline. b Between-group differences in changes from baseline to 6 months. c Adjusted for age. d Adjusted for BMI. Significant p-values (p < 0.05) are indicated in bold.
Figure 3Individual weight change (% of baseline weight) at 6 months by group in a pilot randomised controlled trial for women with recent gestational diabetes who were at risk of developing type 2 diabetes mellitus.